Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 3Unknown 1Recruiting 1Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Fallopian Tube Neoplasms 1Carcinoma, Ovarian Epithelial 1

Interventions

Cisplatin 130Radiotherapy 94Carboplatin 85Fluorouracil 79Paclitaxel 78Cyclophosphamide 77Gemcitabine 72Capecitabine 66Docetaxel 65Doxorubicin 60Oxaliplatin 59Etoposide 57Leucovorin 50Vincristine 47Chemotherapy, Adjuvant 42Cytarabine 38Dexamethasone 35Drug Therapy 33Bevacizumab 31Epirubicin 29Neoadjuvant Therapy 28Pemetrexed 27Tamoxifen 25Irinotecan 25Prednisone 24Rituximab 21Methotrexate 21Radiotherapy, Intensity-Modulated 19apatinib 18Vinorelbine 18

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Unknown × mirvetuximab soravtansine × Clear all
NCT05622890 2022-11-21

A Single-arm Clinical Trial of IMGN853 in Chinese Adult Patients With Platinum-resistant, Epithelial Ovarian Cancer

Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.

Phase 3 Unknown
35 enrolled
Gynecologic

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡